Stockscreener 앱 받기
0.3213
48.06%
0.1043
시장 영업 전:
.32
-0.0013
-0.40%
Allakos Inc 주식(ALLK)의 최신 뉴스
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc.ALLK - PR Newswire
Allakos Inc Inc. (ALLK) Price Performance: A Technical Analysis Perspective - investchronicle.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Allakos, Inc. (ALLK) - TradingView
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Tang Capital’s Concentra nabs a win, making a deal to buy Allakos - Endpoints News
Allakos to be acquired by Concentra Biosciences for 33c per share in cash - TipRanks
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders - The Joplin Globe
Allakos Announces Merger Agreement with Concentra Biosciences - TipRanks
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders - Bluefield Daily Telegraph
Allakos agrees to Concentra Biosciences acquisition - Investing.com
Allakos stock surges on reverse merger deal (ALLK:NASDAQ) - Seeking Alpha
Allakos to Be Acquired for 33 Cents a Share - MarketWatch
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - The Manila Times
Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences - MarketScreener
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in - Bluefield Daily Telegraph
Biotech Deal Alert: Concentra Biosciences Acquires AllakosKey Terms Revealed - Stock Titan
ALLK ALERT: ROSEN, A LEADING FIRM, Reminds Allakos Inc. Investors of Important May 11th Deadline in Securities Class Action First Filed By Firm- ALLK - ACCESS Newswire
Allakos stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa
Allakos stock plunges to 52-week low of $0.23 amid market challenges - Investing.com India
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Allakos Inc. (NASDAQ:ALLK) Short Interest Update - Defense World
Analyzing Allakos (NASDAQ:ALLK) and Acerus Pharmaceuticals (OTCMKTS:TRLPF) - Defense World
Allakos Inc.: Hold Rating Amid Restructuring and Financial Uncertainty - TipRanks
Allakos faces potential Nasdaq delisting over share price By Investing.com - Investing.com Australia
Allakos Reports Q4 2024 Results Amid Strategic Shift - TipRanks
Allakos faces potential Nasdaq delisting over share price - Investing.com India
Allakos Inc. (ALLK) reports earnings - Quartz
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results - The Manila Times
Allakos Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Allakos Swings to Surprise Q4 Profit as Major Restructuring Takes Shape - StockTitan
Allakos (ALLK) Projected to Post Quarterly Earnings on Thursday - Defense World
The Curious Case of Allakos - substack.com
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Losses to Contact Its Attorneys: 3 DAY APPLICATION DEADLINE ALERT - ACCESS Newswire
Allakos Inc. (ALLK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Lee joins Lycia as CMO - BioCentury
It is Poised to be a Bull Market for Allakos Inc (ALLK) - SETE News
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - EIN News
Introducing Our Rant Against Allakos Inc - US Post News
FY2024 EPS Estimates for Allakos Lowered by Leerink Partnrs - Defense World
Allakos Inc [ALLK] Officer makes an insider purchase of 21,116 shares worth 23219.0. - Knox Daily
This Week’s 14.26% Gain In Allakos Inc (NASDAQ: ALLK) Taught Us Something New - Marketing Sentinel
Evaluating Allakos: Strategic Review, NOL Potential, and Kevin Tang's Activist Stake Amidst Biopharma Challenges - Smartkarma
What To Expect From Eli Lilly’s (LLY) Q4 Earnings - The Globe and Mail
Chronic Spontaneous Urticaria Market Set to Grow Substantially - openPR
Such Is The Power Of Allakos Inc (NASDAQ: ALLK) - Stocks Register
Allakos Inc: -85.21% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Allakos Inc - GuruFocus
Allakos stock tanks after company announces mass layoffs - MSN
The time has not yet come to remove your chips from the table: Allakos Inc (ALLK) - SETE News
Allakos stock plunges to 52-week low of $0.23 amid steep annual decline - Investing.com
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok - Benzinga India
Allakos stock tumbles following AK006 trial discontinuation - MSN
Bay Area biotech firm guts staff, shuts trial after dangerous side effects - SFGATE
Allakos plunges 75% on phase 1 data for urticaria asset - MSN
Allakos (NASDAQ:ALLK) Cut to Hold at Piper Sandler - Defense World
Allakos (NASDAQ:ALLK) Cut to Hold at Citizens Jmp - Defense World
Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade - MSN
BioAge drops obesity drug; Akero, 89bio cash in on MASH data - BioPharma Dive
Allakos to cease AK006 development after trial setback - MSN
2.00%
자본화:
|
볼륨(24시간):